RNS Number : 2051U
ReNeuron Group plc
06 April 2021

ReNeuron Group plc

("ReNeuron" or the "Company")


Virtual conference attendance and presentations

CEO and CMO to present at Cell & Gene Meeting on the Mediterranean

CEO to present at the Investing in Cures Summit


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at two virtual conferences, the virtual Cell & Gene Meeting on the Mediterranean ('Meeting on the Med') conference, which takes place on 6-9 April 2021 and the Investing in Cures Summit, "Latest Advances from Clinical Trials and Industry Partnership", on 12-17 April 2021.


The Meeting on the Med conference is organised by the Alliance for Regenerative Medicine and brings together specialists and companies in the cell and gene therapy community from across Europe. It will be delivered virtually and includes a mix of on demand content that will be released each morning and two live-stream panels each day. Virtual attendees will have access to presentations from over 80 companies, virtual exhibit booths and panel chats.


Richard Beckman, Chief Medical Officer of ReNeuron, will chair a meeting titled "Gene Therapies for Ophthalmologic Diseases" as part of the on-demand content available from Tuesday 6 April. The panel will discuss aspects of the eye and ocular disease that make it an attractive target for cell and gene therapy, as well as potential future developments that may occur in the space. CEO, Olav Hellebø, will also be presenting at the event providing an overview and highlighting the Company's technical and clinical achievements over the past 12 months.


For more information and to register for the event, please visit:


The Investing in Cures Summit, hosted by the Foundation Fighting Blindness and Retinal Degeneration Fund, is a limited-attendance summit that engages key stakeholders, key opinion leaders, clinical trial investigators, and companies advancing promising therapies. As part of a series of webcasts focused on therapies in development to address retinal degenerations, Olav Hellebø will host a presentation focusing on ReNeuron's technologies and business objectives in the retinal disease space.


No new material will be disclosed at these events and the presentations will be available on the Company website following the events:





Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Michael Hunt, Chief Financial Officer




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600




Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

Tim Sohal (Sales & Corporate Broking)


Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654


About ReNeuron


ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.